<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01849796</url>
  </required_header>
  <id_info>
    <org_study_id>148-10</org_study_id>
    <nct_id>NCT01849796</nct_id>
  </id_info>
  <brief_title>Transcranial Stimulation (tDCS) For the Treatment of Neuropathic Facial Pain</brief_title>
  <acronym>TDCS</acronym>
  <official_title>Transcranial Stimulation (TDCS) For The Treatment of Neuropathic Facial Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beth Israel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beth Israel Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to determine if transcranial direct current stimulation (tDCS, the device that&#xD;
      regulates brain activity, can improve pain in people with neuropathic facial pain and compare&#xD;
      which modality (inhibitory tDCS over the somatosensory cortex or excitatory tDCS over the&#xD;
      motor cortex) can result in better pain-relief.)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a pilot study designed to collect preliminary data on safety and efficacy of&#xD;
      transcranial direct current stimulation (tDCS)to relieve pain in subjects with neuropathic&#xD;
      facial pain,and to compare two pain-treatment tDCS modalities: inhibitory tDCS stimulation&#xD;
      over the somatosensory cortex and excitatory tDCS over the motor cortex.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Investigators moved to other institutions&#xD;
  </why_stopped>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome will be a composite measure &quot;Pain intensity/consumption of pain medication&quot;.</measure>
    <time_frame>Daily from Baseline to up to 17 weeks</time_frame>
    <description>The washout period between phase I and phase II of the study is variable as patients have to go back to their baseline.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Facial Pain</condition>
  <arm_group>
    <arm_group_label>Group A: Anodal tDCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A will receive one block of real excitatory anodal tDCS over the motor cortex and one block of sham.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: Cathodal tDCS</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Group B will receive one block of inhibitory cathodal tDCS over the somatosensory cortex and one block of sham.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>tDCS</intervention_name>
    <description>TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.</description>
    <arm_group_label>Arm B: Cathodal tDCS</arm_group_label>
    <arm_group_label>Group A: Anodal tDCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Spontaneous facial neuropathic pain due to any of following:&#xD;
&#xD;
               1. Trigeminal neuralgia, type 1, (TN1): facial pain of spontaneous onset with&#xD;
                  predominantly episodic pain.&#xD;
&#xD;
               2. Trigeminal neuralgia, type 2, (TN2): facial pain of spontaneous onset with&#xD;
                  predominantly constant pain.&#xD;
&#xD;
               3. Trigeminal neuropathic pain, (TNP): facial pain resulting from unintentional&#xD;
                  injury to the trigeminal system from facial trauma, oral surgery, ear, nose and&#xD;
                  throat (ENT) surgery, root injury from posterior fossa or skull base surgery,&#xD;
                  stroke, etc.&#xD;
&#xD;
               4. Trigeminal deafferentation pain, (TDP): facial pain in a region of trigeminal&#xD;
                  numbness resulting from intentional injury to the trigeminal system from&#xD;
                  neurectomy, gangliolysis, rhizotomy, nucleotomy, tractotomy, or other denervating&#xD;
                  procedures.&#xD;
&#xD;
               5. Symptomatic trigeminal neuralgia, (STN): facial pain resulting from multiple&#xD;
                  sclerosis.&#xD;
&#xD;
             e) Postherpetic neuralgia, (PHN): facial pain resulting from trigeminal Herpes zoster&#xD;
             (shingles) outbreak in the trigeminal distribution.&#xD;
&#xD;
          -  Pain intensity score for &quot;worst pain in the last 24 hours&quot; &gt;4 on a numeric scale 0-10&#xD;
             at the time of enrollment and before the first stimulation of each treatment block.&#xD;
&#xD;
          -  Pain intensity score for &quot;pain right now&quot; &gt;4 on a numeric scale 0-10 before the first&#xD;
             stimulation of each block of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Uncontrolled hypertension, uncontrolled diabetes, uncontrolled cardiovascular disease&#xD;
&#xD;
          -  Other painful conditions than neuropathic facial pain, that are not related to and&#xD;
             can't be distinguished from the neuropathic facial pain&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Implanted neurostimulation devices (e.g. a spinal cord stimulator, a deep brain&#xD;
             stimulator, etc)&#xD;
&#xD;
          -  Active illegal drug/alcohol abuse&#xD;
&#xD;
          -  Unable to follow directions or complete tools in English.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joy Hao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beth Israel Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beth Israel Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://stoppain.org/</url>
    <description>Department of Pain Medicine and Palliative Care</description>
  </link>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>December 27, 2012</study_first_submitted>
  <study_first_submitted_qc>May 6, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 9, 2013</study_first_posted>
  <last_update_submitted>December 9, 2015</last_update_submitted>
  <last_update_submitted_qc>December 9, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tDCS</keyword>
  <keyword>Neuropathic</keyword>
  <keyword>Facial</keyword>
  <keyword>Pain</keyword>
  <keyword>Neuralgia</keyword>
  <keyword>deafferentation</keyword>
  <keyword>Trigeminal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
    <mesh_term>Facial Pain</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

